IDH1 and acute myeloid leukemia: Mutations in IDH1/2 have been reported to confer sensitivity to several chemotherapeutic agents in most cancer types, including colorectal cancer[53], glioma[54,55], cholangiocarcinoma[53,56], and AML[50,57].